CINECA IRIS Institutional Research Information System

BARDELLI, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.375
EU - Europa 17.409
AS - Asia 14.776
SA - Sud America 590
OC - Oceania 411
AF - Africa 175
Continente sconosciuto - Info sul continente non disponibili 46
Totale 60.782
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.478
CN - Cina 9.034
IT - Italia 5.083
DE - Germania 1.984
GB - Regno Unito 1.692
JP - Giappone 1.451
FR - Francia 1.396
IE - Irlanda 1.094
SE - Svezia 904
ES - Italia 839
KR - Corea 797
CA - Canada 678
IN - India 666
FI - Finlandia 632
UA - Ucraina 630
SG - Singapore 611
NL - Olanda 566
HK - Hong Kong 490
PL - Polonia 475
TW - Taiwan 373
AU - Australia 330
TR - Turchia 318
BE - Belgio 298
CH - Svizzera 292
AT - Austria 253
GR - Grecia 245
VN - Vietnam 241
BR - Brasile 236
DK - Danimarca 192
MX - Messico 187
RU - Federazione Russa 150
RO - Romania 131
TH - Thailandia 125
IL - Israele 120
CZ - Repubblica Ceca 107
PT - Portogallo 101
HU - Ungheria 90
NO - Norvegia 87
NZ - Nuova Zelanda 80
CO - Colombia 78
PE - Perù 78
AR - Argentina 72
IR - Iran 69
CL - Cile 62
ID - Indonesia 58
MY - Malesia 54
SA - Arabia Saudita 54
PK - Pakistan 37
AM - Armenia 35
EC - Ecuador 35
JO - Giordania 34
SN - Senegal 34
PH - Filippine 33
EG - Egitto 31
EU - Europa 26
HR - Croazia 25
NG - Nigeria 25
LB - Libano 24
SK - Slovacchia (Repubblica Slovacca) 22
MO - Macao, regione amministrativa speciale della Cina 21
AE - Emirati Arabi Uniti 20
ZA - Sudafrica 20
SI - Slovenia 19
KZ - Kazakistan 16
TN - Tunisia 14
AP - ???statistics.table.value.countryCode.AP??? 13
BA - Bosnia-Erzegovina 13
MA - Marocco 13
GY - Guiana 12
PS - Palestinian Territory 12
RS - Serbia 12
LU - Lussemburgo 11
QA - Qatar 11
BD - Bangladesh 10
BG - Bulgaria 10
BY - Bielorussia 10
CY - Cipro 10
DZ - Algeria 10
PR - Porto Rico 10
UZ - Uzbekistan 10
EE - Estonia 9
BN - Brunei Darussalam 8
IS - Islanda 8
LT - Lituania 8
UY - Uruguay 8
LV - Lettonia 7
MK - Macedonia 7
MU - Mauritius 7
GE - Georgia 6
GH - Ghana 6
KE - Kenya 6
NI - Nicaragua 6
PA - Panama 6
KH - Cambogia 5
OM - Oman 5
A1 - Anonimo 4
BO - Bolivia 4
ET - Etiopia 4
IQ - Iraq 4
MN - Mongolia 4
Totale 60.741
Salva come PNG Salva come JPEG
Città #
Ann Arbor 6.407
Beijing 2.451
Chandler 1.603
Houston 1.199
Shanghai 1.109
Fairfield 1.072
Dublin 1.041
Redwood City 948
Dearborn 871
Torino 763
Hangzhou 669
Ashburn 633
Wilmington 616
Guangzhou 608
Seattle 577
Woodbridge 552
Cambridge 539
Milan 428
Jacksonville 414
Tokyo 396
Villeurbanne 373
Nanjing 371
New York 338
Singapore 332
Medford 319
Princeton 314
Nyköping 305
Fremont 290
Turin 287
Pisa 277
Boston 250
Warsaw 248
Buffalo 236
Rome 210
Taipei 200
Wuhan 199
London 188
Chengdu 182
Vienna 178
Barcelona 177
Boardman 155
Lappeenranta 152
Paris 145
San Diego 145
Toronto 145
Los Angeles 142
Seoul 137
Shenyang 133
Zhengzhou 124
Amsterdam 123
Dong Ket 123
Duncan 121
Ottawa 120
Jinan 117
Berlin 114
Chicago 114
Changsha 109
Shenzhen 109
Madrid 102
Munich 101
Brussels 100
Tianjin 99
Norwalk 95
Central District 92
Central 91
Istanbul 86
Hong Kong 84
Chongqing 81
Rochester 81
Washington 80
Helsinki 79
Hefei 73
San Francisco 71
Falls Church 70
Philadelphia 70
Xian 69
Bologna 63
Heidelberg 63
Nanchang 63
Phoenix 63
Utrecht 63
Bangkok 62
Pune 61
Carrara 59
Lima 58
Manchester 57
San Mateo 57
Silver Spring 57
Genoa 56
Sydney 56
Fuzhou 55
Kunming 55
Mumbai 55
Southend 54
Verona 54
Chennai 52
Grafing 52
Baltimore 51
Hyderabad 51
Melbourne 50
Totale 33.389
Salva come PNG Salva come JPEG
Nome #
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial 4.997
High-dose Vitamin C enhances cancer immunotherapy 4.227
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR 3.872
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. 2.125
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth 1.769
Adaptive mutability of colorectal cancers in response to targeted therapies 1.693
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 1.302
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations 1.129
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer 1.048
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo letter 1.005
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model 841
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies 788
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor 690
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer 650
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 610
Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities 573
Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer 562
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer 556
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology 547
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients 542
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets 483
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer 481
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. 467
MET mutations in cancers of unknown primary origin (CUPs). 433
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer 430
Costruzione di linee cellulari isogeniche per mutazioni associate al cancro e loro applicazione per approcci di farmacogenomica 408
Toward understanding and exploiting tumor heterogeneity 399
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients 364
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition 359
MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patients 356
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. 327
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer 319
Preclinical models for precision oncology 305
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS 301
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group 298
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer 294
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer 280
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 267
BRAF V600E is a determinant of sensitivity to proteasome inhibitors. 260
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 246
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. 245
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case 241
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. 240
Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions 235
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers 234
How liquid biopsies can change clinical practice in oncology 234
Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature 225
Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis 222
Exploiting DNA repair defects in colorectal cancer 221
Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective population-based Consortium analysis 220
Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients 219
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs 215
Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti– Epidermal Growth Factor Receptor Antibody Therapies 213
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 210
TGF-α and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. 208
Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer 208
Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy? 206
Somatic alterations as the basis for resistance to targeted therapies 204
Early-onset colorectal cancer in young individuals 201
Sensitivity to Entrectinib Associated with a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer 200
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial 199
Evolving neoantigen profiles in colorectal cancers with DNA repair defects 198
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin 193
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer 192
Liquid biopsy: monitoring cancer-genetics in the blood 191
Acquired resistance to EGFR-targeted therapies in colorectal cancer. 191
The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. 188
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients 182
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer 181
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. 180
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. 176
Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases 172
Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene. 167
High frequency of mutations of the PIK3CA gene in human cancers 167
Circulating pEGFR is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer. 165
Minimal residual disease in breast cancer: in blood veritas. 163
Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway 162
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer 158
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. 155
Tumor evolution as a therapeutic target 155
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia 155
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer 154
Tracking colorectal cancer evolution in time and space 150
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer 150
Mutational profiling of kinases in glioblastoma. 149
Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer 148
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers 146
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia 144
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 144
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma 144
Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. 141
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. 141
Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. 140
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer 140
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer 140
Kras mutations and resistance to anti-egfr treatment 139
Autophosphorylation promotes complex formation of recombinant hepatocyte growth factor receptor with cytoplasmic effectors containing SH2 domains. 139
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance 139
MLK4 gene, a new diagnostic and prognostic marker in cancers 138
Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers 136
Totale 47.416
Salva come PNG Salva come JPEG
Categoria #
all - tutte 118.508
article - articoli 0
book - libri 0
conference - conferenze 3.799
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 122.307
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.782 0 391 508 879 737 1.208 773 544 755 796 743 448
2020/20219.549 480 441 677 719 784 758 937 583 918 876 650 1.726
2021/202213.112 1.859 1.855 1.585 2.008 659 546 700 651 680 534 1.101 934
2022/20238.940 708 680 506 791 664 1.394 799 647 957 473 731 590
2023/20248.064 746 760 642 673 698 753 557 669 224 832 709 801
2024/2025624 505 119 0 0 0 0 0 0 0 0 0 0
Totale 62.185